Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
iPrEx
About the Trial
The Pre Exposure Prophylaxis Initiative trial randomized 2,499 men and transgender women who have sex with men to daily oral tenofovir emtricitabine or placebo. PrEP reduced HIV acquisition by 44 percent overall, but by up to 92 percent among participants with detectable drug levels, establishing that adherence drives protection. iPrEx led to the 2012 FDA approval of Truvada as PrEP, the first biomedical HIV prevention pill. Follow up trials, Partners PrEP and TDF2 in heterosexuals, confirmed class wide benefit. PrEP transformed HIV prevention into a consumer controlled daily option and became a cornerstone of ending the epidemic strategies.
Related Trials
Diabetes Prevention Program
The DPP randomized 3,234 people with impaired glucose tolerance to metformin, intensive lifestyle modification, or placebo. Lifest...
LOOK AHEAD
LOOK AHEAD randomized over 5,100 overweight or obese adults with type 2 diabetes to intensive lifestyle intervention targeting 7 p...
WOSCOPS
The West of Scotland Coronary Prevention Study randomized 6,595 healthy men with elevated LDL cholesterol to pravastatin or placeb...
Heart Protection Study
HPS randomized 20,536 UK adults with vascular disease or diabetes to simvastatin 40 mg or placebo regardless of baseline cholester...